Renal cell carcinoma expansion creating lenvatinib opportunity — lenvatinib's FDA approval in combination with pembrolizumab (KEYNOTE-581 trial) for first-line advanced RCC treatment — demonstrating superior progression-free survival compared to sunitinib monotherapy — establishing lenvatinib as an emerging option within the rapidly evolving RCC treatment landscape where...